Alzheimer disease (AD) is the sixth leading cause of death in the US, but existing treatments provide only a modest improvement in symptoms. To our knowledge, no approved treatment exists that improves the course of disease or underlying pathology. Research on disease-modifying AD treatments has proven to be extremely challenging, with a number of major recent clinical trials of drug therapies resulting in negative or ambivalent findings.1,2 While many alternative ideas for developing a treatment for AD are being pursued, 2 key strategies have emerged: initiating interventions earlier in the course of disease in individuals who are at risk but unimpaired and identifying targets beyond abnormal amyloid and tau proteins, the pathology that defines AD.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Landau SM, Harrison TM. A Link Between Cardiovascular Risk Management and Alzheimer Disease Is Still Elusive. JAMA Neurol. Published online March 08, 2021. doi:10.1001/jamaneurol.2021.0083
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: